Oncomatryx Biopharma
Mikel Ochotorena Elicegui is a finance professional with significant experience in financial management and auditing. Currently serving as Finance Manager at Oncomatryx Biopharma since March 2021, Mikel previously held the position of Responsable Económico-Financiero at Amenabar Promociones Residenciales from April 2019 to March 2021. Prior experience includes a role as Auditor Senior at KPMG from October 2015 to April 2019. Mikel began a career in finance with internships at Arista, Kutxabank, and Estudio de Arquitectura y Urbanismo Arkites S.L. Mikel's academic background includes a degree in Business Administration and Management from the University of Deusto, along with ongoing education at ISC Paris.
This person is not in any teams
Oncomatryx Biopharma
Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment.Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma.Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumorinvasiveness, drug resistance and immunosuppression.Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.